胞壁酰二肽处理对小鼠抗弓形虫感染能力的影响。
Effects of muramyl dipeptide treatment on resistance to infection with Toxoplasma gondii in mice.
作者信息
Krahenbuhl J L, Sharma S D, Ferraresi R W, Remington J S
出版信息
Infect Immun. 1981 Feb;31(2):716-22. doi: 10.1128/iai.31.2.716-722.1981.
Abstract
Studies were carried out to determine whether treatment of mice with the synthetic adjuvant muramyl dipeptide afforded any resistance to infection with the obligate intracellular protozoan Toxoplasma gondii. Marked resistance to lethal challenge infection was observed in CBA but not C57BL/6 mice pretreated with muramyl dipeptide. In CBA mice, a single muramyl dipeptide treatment administered 14, 7, or 4 days before Toxoplasma challenge did not afford protection, whereas mice treated at -1 day were highly resistant. Additional studies carried out to investigate the mechanisms underlying the enhanced resistance to Toxoplasma in muramyl dipeptide-treated mice failed to reveal either enhanced cytolytic antibodies to the parasite or evidence that peritoneal macrophages from treated mice were activated as determined in vitro by their microbicidal capacity for Toxoplasma or cytotoxic capacity for tumor target cells.
摘要
开展了多项研究，以确定用合成佐剂胞壁酰二肽处理小鼠是否能使其对专性细胞内原生动物刚地弓形虫的感染产生任何抗性。在用胞壁酰二肽预处理的CBA小鼠中观察到对致死性攻击感染有显著抗性，但C57BL/6小鼠中未观察到。在CBA小鼠中，在弓形虫攻击前14天、7天或4天进行单次胞壁酰二肽处理未提供保护作用，而在攻击前1天处理的小鼠具有高度抗性。为研究胞壁酰二肽处理的小鼠对弓形虫抗性增强的潜在机制而开展的其他研究，未能揭示对该寄生虫的溶细胞抗体增强，也未发现证据表明处理过的小鼠的腹腔巨噬细胞通过其对弓形虫的杀菌能力或对肿瘤靶细胞的细胞毒性能力在体外测定时被激活。
相似文献
1
Effects of muramyl dipeptide treatment on resistance to infection with Toxoplasma gondii in mice.
Infect Immun. 1981 Feb;31(2):716-22. doi: 10.1128/iai.31.2.716-722.1981.
2
Effects of treatment with muramyl dipeptide and certain of its analogs on resistance to Listeria monocytogenes in mice.
Infect Immun. 1980 Nov;30(2):462-6. doi: 10.1128/iai.30.2.462-466.1980.
3
Effects of muramyl dipeptide and trehalose dimycolate on resistance of mice to Toxoplasma gondii and Acanthamoeba culbertsoni infections.
Int Arch Allergy Appl Immunol. 1986;81(2):112-7. doi: 10.1159/000234118.
4
Comparison of cytotoxic and microbicidal function of bronchoalveolar and peritoneal macrophages.
Immunology. 1981 Apr;42(4):513-9.
5
In vivo regulation of humoral and cellular immune responses of mice by a synthetic adjuvant, N-acetyl-muramyl-L-alanyl-D-isoglutamine, muramyl dipeptide for MDP.
Cell Immunol. 1979 Jun;45(1):199-206. doi: 10.1016/0008-8749(79)90377-0.
6
Immunoadjuvant effects of the synthetic muramyl-dipeptide (MDP) N-acetylmuramyl-L-alanyl-D-isoglutamine.
Z Immunitatsforsch Immunobiol. 1978 Oct;155(1):87-92.
7
Recent developments concerning muramyl dipeptide, a synthetic immunoregulating molecule.
J Reticuloendothel Soc. 1979 Dec;26(Suppl):631-41.
8
Marked enhancement in vivo of adjuvant activity of muramyl dipeptide to protein antigens and to synthetic weak immunogens with monoclonal anti-muramyl dipeptide antibodies.
Infect Immun. 1985 Aug;49(2):312-9. doi: 10.1128/iai.49.2.312-319.1985.
9
Activation of mouse peritoneal adherent cells with N-acyl muramyl dipeptide derivatives.
Infect Immun. 1985 Mar;47(3):665-9. doi: 10.1128/iai.47.3.665-669.1985.
10
Protective effect of muramyl dipeptide analogs against infections of Pseudomonas aeruginosa or Candida albicans in mice.
Infect Immun. 1981 Dec;34(3):676-83. doi: 10.1128/iai.34.3.676-683.1981.
引用本文的文献
1
The cat's out of the bag: Toxoplasma gondii provides further insight into myeloid-mediated host defense.
Immunohorizons. 2025 Aug 25;9(9). doi: 10.1093/immhor/vlaf037.
2
Trained immunity: novel perspectives in diabetes and associated complications.
Front Immunol. 2025 Jul 17;16:1613602. doi: 10.3389/fimmu.2025.1613602. eCollection 2025.
3
Immunization with Complete Freund's Adjuvant Reveals Trained Immunity-like Features in A/J Mice.
Vaccines (Basel). 2025 Jul 21;13(7):768. doi: 10.3390/vaccines13070768.
4
Repeated and alternate stimulations with dsRNA and SEB alter responses in macrophages and epithelial cells.
World Allergy Organ J. 2025 Jan 24;18(2):101026. doi: 10.1016/j.waojou.2025.101026. eCollection 2025 Feb.
5
Role of Trained Immunity in Heath and Disease.
Curr Cardiol Rep. 2025 Jan 13;27(1):18. doi: 10.1007/s11886-024-02167-7.
6
Infection-induced trained immunity: a twist in paradigm of innate host defense and generation of immunological memory.
Infect Immun. 2025 Jan 31;93(1):e0047224. doi: 10.1128/iai.00472-24. Epub 2024 Dec 10.
7
Induction of trained immunity in broiler chickens following delivery of oligodeoxynucleotide containing CpG motifs to protect against Escherichia coli septicemia.
Sci Rep. 2024 Aug 14;14(1):18882. doi: 10.1038/s41598-024-69781-x.
8
Type-I interferons promote innate immune tolerance in macrophages exposed to Mycobacterium ulcerans vesicles.
PLoS Pathog. 2023 Jul 10;19(7):e1011479. doi: 10.1371/journal.ppat.1011479. eCollection 2023 Jul.
9
Trained innate immunity, epigenetics, and food allergy.
Front Allergy. 2023 May 26;4:1105588. doi: 10.3389/falgy.2023.1105588. eCollection 2023.
10
The mechanisms and cross-protection of trained innate immunity.
Virol J. 2022 Dec 8;19(1):210. doi: 10.1186/s12985-022-01937-5.
本文引用的文献
1
Effects of treatment with muramyl dipeptide and certain of its analogs on resistance to Listeria monocytogenes in mice.
Infect Immun. 1980 Nov;30(2):462-6. doi: 10.1128/iai.30.2.462-466.1980.
2
Effects of human peripheral blood monocytes, monocyte-derived macrophages, and spleen mononuclear phagocytes on Toxoplasma gondii.
Cell Immunol. 1980 Sep 1;54(2):330-50. doi: 10.1016/0008-8749(80)90214-2.
3
Immunostimulant activities of a lipophilic muramyl dipeptide derivative and of desmuramyl peptidolipid analogs.
Infect Immun. 1980 Mar;27(3):826-31. doi: 10.1128/iai.27.3.826-831.1980.
4
Serological and immunochemical characterization of monoclonal antibodies to Toxoplasma gondii.
Immunology. 1980 Aug;40(4):579-88.
5
Cytostatic effects of activated macrophages on tumor target cells: inhibition of cytotoxic action of ARA-C.
J Immunopharmacol. 1980;2(3):325-48. doi: 10.3109/08923978009046465.
6
Macrophage stimulation in vitro by an inactive muramyl dipeptide derivative after conjugation to a multi-poly(DL-alanyl)-poly(L-lysine) carrier.
Infect Immun. 1980 Apr;28(1):1-5. doi: 10.1128/iai.28.1.1-5.1980.
7
Failure of synthetic muramyl dipeptide to increase antibacterial resistance.
Infect Immun. 1980 Feb;27(2):288-91. doi: 10.1128/iai.27.2.288-291.1980.
8
The influence of immunologically committed lymphoid cells on macrophage activity in vivo.
J Exp Med. 1969 May 1;129(5):973-92. doi: 10.1084/jem.129.5.973.
9
Scanning electron microscopy of Toxoplasma gondii.
J Gen Microbiol. 1973 Mar;75(1):111-8. doi: 10.1099/00221287-75-1-111.
10
A role for activated macrophages in resistance to infection with Toxoplasma.
Infect Immun. 1972 Nov;6(5):829-34. doi: 10.1128/iai.6.5.829-834.1972.
Zotero 插件